Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; COVID-19 Vaccine, which is in Phase 2b clinical trial for the treatment of SARS-CoV-1, SARS-CoV-2, and Middle East respiratory syndrome coronavirus; Seasonal Influenza vaccine, which is in Phase 2 clinical trial, to treat H1N1 Influenza; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California. Show more
170 Harbor Way, South San Francisco, CA, 94080, United States
Market Cap
147.3M
52 Wk Range
$0.26 - $0.84
Previous Close
$0.60
Open
$0.59
Volume
254,790
Day Range
$0.59 - $0.64
Enterprise Value
69.96M
Cash
63.81M
Avg Qtr Burn
N/A
Insider Ownership
1.57%
Institutional Own.
0.05%
Qtr Updated
12/31/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
VXA-CoV2-1 oral pill Details COVID-19 | Phase 2b Data readout | |
Monovalent Norovirus Vaccine Details Norovirus | Phase 2b Update | |
Oral Bivalent Norovirus Vaccine Details Norovirus | Phase 2 Update | |
VXA-A1.1 Details Influenza | Phase 2 Update | |
Phase 1 Data readout | ||
Oral Bivalent Norovirus Vaccine Details Norovirus | Phase 1 Update |
